Clinical trial findings from previous MS studies indicate that NeuroVax(TM) induces strong, disease-specific immune responses in essentially all the MS patients treated. IRBP is planning a new Phase 2B Clinical Trial to launch a 200-patient trial by 2013 in the United States that will test the clinical benefit of NeuroVax(TM) by assessing its effect on MRI and relapse rates.
Previous clinical trial data indicates that NeuroVax can play an important part of inducing strong disease-specific immune responses and provides a stimulation of FOXP3+ Regulatory T-cells.
“We are a growth company with perhaps one of the best MS drugs to ever be developed, the difference between NeuroVax and current treatments is this drug actually does what it is supposed to do which is invoke strong immune responses with stimulation of FOXP3+ T-cells. We have the winning drug and the winning team to develop NeuroVax to market” Mr. Buswell COO IRBP.
NeuroVax Video http://immuneresponsebiopharma.com/NeuroVaxVaccine.aspx
The Scientific Advisory Board guiding the development of NeuroVax(TM) will consist of five initial members:
Dr. Dennis Bourdette is Chair and the Roy and Eulalia Swank Research Professor in the Department of Neurology at Oregon Health and Science University (OHSU), where he has been a faculty member since 1983. He was the lead clinician investigator on the early trials of TCR peptide vaccination in MS. Dr. Bourdette has published numerous articles related to MS and is listed in the Best Doctors in America.
Dr. Arthur Vandenbark is a senior research career scientist at the Portland Veterans Affairs Medical Center, and a professor in the Departments of Neurology and Molecular Microbiology and Immunology at OHSU. An inventor and pioneer of the TCR peptide vaccination approachfor MS & helped develop the FOXP3+ Expression technology the mechanism of action for NeuroVax.
Dr. Halina Offner is a Professor in the Department of Neurology at Oregon Health & Science University (OHSU) in Portland, Oregon with a joint appointment in the Department of Anesthesiology and Peri-Operative Medicine. Her work is extensively published, with over 250 articles and book chapters in press.
Dr. Richard Bartholomew is an industry veteran with over 30 years’ of experience in developing treatments for Auto-Immune diseases. He earned his PhD in Biochemistry/Immunology at the University of Utah Medical Center and has led the AI program including the development of NeuroVax for Immune Response as VP of R&D. Additionally Dr. Bartholomew helped co-develop the FOXP3+ Expression technology the mechanism of action for NeuroVax.
Dr. Ronald Moss is also an industry veteran with over 25 years of experience in clinical development of new therapies and drugs for the treatment of Auto-Immune and Infectious Diseases, a recognized expert in these fields adds a wealth of expertise and knowledge to the SAB to help guide & develop NeuroVax for MS.
Full Press Release available at www.immuneresponsebiopharma.com
